Fella Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026.
About
Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.